351. Anti-tumor efficacy and pre-clinical immunogenicity of IFNα2a-NGR
- Author
-
Shuhong Dong, Yingqi Zhang, Bei Gao, Baolai Zhang, and Yong-Jie Wu
- Subjects
Drug ,Pathology ,medicine.medical_specialty ,Lung Neoplasms ,media_common.quotation_subject ,Recombinant Fusion Proteins ,Mice, Nude ,Peptide ,Antineoplastic Agents ,Interferon alpha-2 ,Toxicology ,law.invention ,Rats, Sprague-Dawley ,Mice ,In vivo ,law ,Cell Line, Tumor ,Medicine ,Animals ,Humans ,Receptors, Immunologic ,media_common ,chemistry.chemical_classification ,Mice, Inbred BALB C ,biology ,business.industry ,Immunogenicity ,Cancer ,Lewis lung carcinoma ,Interferon-alpha ,General Medicine ,medicine.disease ,Macaca mulatta ,Xenograft Model Antitumor Assays ,Recombinant Proteins ,Rats ,chemistry ,Cancer research ,Recombinant DNA ,biology.protein ,Antibody ,business ,Oligopeptides - Abstract
Previously studies have shown that tumor-homing peptide NGR enhances the therapeutic efficacy of human interferon α2a (IFNα2a) against tumors. Here we investigated in vivo anti-tumor effect of recombinant human IFNα2a-NGR (rhIFNα2a-NGR) against human lung adenocarcinoma cell line SPC-A-1, A549 and murine Lewis lung carcinoma (LLC) subcutaneously xenografted tumors and further assessed the immunogenicity of rhIFNα2a-NGR in Sprague Dawley (SD) rats and rhesus monkeys. We found that rhIFNα2a-NGR significantly inhibited the growth of SPC-A-1, A549 and LLC cells-xenografted tumors in a dose-dependent manner. Although the antibodies to rhIFNα were detected in the serum of SD rats and rhesus monkeys treated with rhIFNα2a-NGR, these antibodies did not cause obvious pathological consequence. Taken together, these data demonstrate that rhIFNα2a-NGR has obvious anti-tumor efficacy in vivo, perhaps due to the tumor-homing peptide NGR. Thus rhIFNα2a-NGR represents a promising novel drug for effective treatment of cancer.
- Published
- 2010